Skip to main content

Advertisement

Fig. 3 | Clinical Epigenetics

Fig. 3

From: A novel method for isolation of histones from serum and its implications in therapeutics and prognosis of solid tumours

Fig. 3

Profiling of site-specific histone modifications and modifiers in paired serum and liver tissue of normal and tumour. a (i) Western blots of histones isolated from tissues and serum with site-specific histone PTM antibodies of H4K20Me3, H3K27Me3, H3K9Me3, \( \boldsymbol{\upgamma} \)-H2AX, H3S10P and H4K16Ac in tumour tissue and serum compared to normal. Antibodies against H3 and H4, and fast green-stained histone transferred PVDF membrane were used as equal loading control. b H&E-stained section (×40) of tissues (lung, kidney and brain) from NDEA-treated or untreated (normal) animals. c Western blotting of histones isolated from normal tissues (lung, kidney and brain) and serum of NDEA-treated or untreated animals with site-specific histone PTM antibodies against H4K20Me3, \( \boldsymbol{\upgamma} \)-H2AX, H3S10P and H4K16Ac. Antibodies against H3 and H4, and fast green-stained histone transferred PVDF membrane were used as equal loading control. d Colorimetry-based assay done using serum isolated from normal, early and late stage tumour bearing rats (i) HDAC activity assay was performed on both the TSA-treated and untreated samples (ii) HAT activity. Statistical tests are done by using Student’s t test. *p < 0.05, **p < 0.01

Back to article page